html5-img
1 / 102

Diabetes Mellitus

Reporters: JI Tabajonda, Jennifer M. JI Vio, Rachel Louise S. Diabetes Mellitus. Gross Anatomy. Microscopic Anatomy. Physiology. Glucagon single-chain polypeptide that contains 29 amino acid residues and has a molecular weight of 3483

hali
Télécharger la présentation

Diabetes Mellitus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reporters: JI Tabajonda, Jennifer M. JI Vio, Rachel Louise S. Diabetes Mellitus

  2. Gross Anatomy

  3. Microscopic Anatomy

  4. Physiology • Glucagon • single-chain polypeptide that contains 29 amino acid residues and has a molecular weight of 3483 • increases blood glucose and relaxes smooth muscle of the gastrointestinal tract.  • potent stimulator of hepatic glycogenolysis, gluconeogenesis, and ketogenesis

  5. Insulin Preproinsulin (86 aa) proteolytic processing Proinsulin site specific peptide cleavage C-peptide Insulin

  6. Effects of Insulin

  7. Diabetes Mellitus • Refers to a group of metabolic disorders that share the phenotype of hyperglycemia • With several distinct types • Interaction of genetics and environment • Reduced Insulin secretion • Decreased glucose utilization • Increased glucose production

  8. Classic Symptoms of Diabetes • Polyuria • Polydipsia • Unexplained weight loss

  9. Levels of Glycemia

  10. Criteria for the Dx of DM • Fasting Plasma Glucose (FPG) ≥126 mg/dl (7.0 mmol/L) - Must be repeated on a separate day to confirm diagnosis OR • Postprandial Plasma Glucose (2h PG) ≥200 mg/dl (11.1 mmol/L) -Measured with Oral Glucose Tolerance Test (OGTT) -Must be repeated on a separate days to confirm diagnosis OR

  11. Classic Symptoms + Casual Plasma Glucose (CPG) > 200 mg/dl (> 11.1 mmol/L). -Considered diagnostic of diabetes but should be confirmed on a separate day with FPG or 2hPG. - Casual plasma glucose ( plasma glucose taken without regard to the last meal)

  12. Algorithm for Diagnosing Diabetes Classic Symptoms of DM RBS 140-200 mg/dl (<11.1 mmol/L ≥200 mg/dl (≥11.1 mmol/L) 20PGBS DM <140 mg/dl 140-199 mg/dl ≥200 mg/dl Repeat 20PGBS NORMAL IGT ≥200 mg/dl UERMMC-ISDFI

  13. Asymptomatic Patients Categorize Patients Low Risk High Risk Risk Factors: • BMI > 23kg/m2(w to h ratio >1) or • Waist cir >80 cm F,>90 cm for M • Family Hx of Type 2 diabetes • Age >45 yo • HPN (130/85 mmhg) Risk Factors: • BMI > 23kg/m2(w to h ratio >1) or • Waist cir >80 cm F,>90 cm for M • Family Hx of Type 2 diabetes • Age • HPN (130/85 mmhg)

  14. High risk- Screen as early as 20 years of age FBS <100 mg/dl 100-125 mg/dl (IFG) >/= 126mg/dl NORMAL IFG Rpt FBS <126 mg/dl Check 2hPGBS 2hPGBS Check 2hPGBS <140 mg/dl 140-199 mg/dl >/= 200mg/dl ≥126 mg/dl NORMAL IGT Diabetes

  15. Classification • Type 1 • Complete or near total insulin deficiency • Type 2 • Insulin resistance • impaired insulin secretion • Increased glucose production • Preceded by IFG and IGT

  16. DM Type 3 and 4 • DM type 3 • Other specific types of Diabetes • DM type 4 • Gestational Diabetes Mellitus

  17. Pathophysiology • DM Type I • Complete or near total insulin deficiency • circulating insulin is very low or absent • plasma glucagon • and the pancreatic beta cells fail to respond to all insulin-secretory stimuli.

  18. Pathophysiology of DM Type I • Autoimmune • islet cell antibodies • anti-insulin antibodies • genetic susceptibility • HLA markers • Infectious and/or environmental agents ? •  viruses (eg, mumps, rubella, Coxsackie B4), toxic chemicals, exposure to cow's milk in infancy, and cytotoxins

  19. Dm Type 2 • Predominantly insulin resistance with relative insulin deficiency to predominantly insulin deficiency with insulin resistance • Excessive hepatic glucose production • Abnormal fat metabolism *Insulin resistance, is the decreased ability of insulin to act effectively on target tissues (especially muscle, liver, and fat)

  20. GDM • Any degree of glucose intolerance with the onset or first recognition during pregnancy • Does not exclude the possibility that undiagnosed glucose intolerance may have occurred prior to pregnancy • Usually 24-48 weeks

  21. Pathophysiology • Placental hormones causing insulin resistance • Estrogen, progesterone, cortisol, HPL • Decreased insulin secretion • Borderline pancreatic function, cannot produce insulin levels to meet metabolic needs

  22. Pre-Diabetes • Impaired Fasting glucose • FBS of 100-125 mg/dL • IGT • 2HPGBS 140-199 mg/dL • Associated withthe metabolic syndrome, which includes obesity (especially abdominalor visceral obesity), dyslipidemia of the high-triglycerideand/or low-HDL type, and hypertension.

  23. Complications of Diabetes Mellitus ACUTE Diabetic Ketoacidosis (DKA) Hyperglycemic Hyperosmolar State (HHS) CHRONIC: Macrovascular (CAD,CVD,PVD) Microvascular (retinopathy, nephropathy, neuropathy) Others (e.g. GI, GU, Dermatologic, Infectious)

  24. Acute Complications of DM DKA and HHS are medical emergencies • associated with potentially serious complications if not promptly diagnosed and treated. • associated with absolute or relative insulin deficiency, volume depletion, and acid-base abnormalities.

  25. DKA vs HHS

  26. DKA • Can occur in both type 1 and type 2 DM • Signs & symptoms develop over 24hrs • results from relative or absolute insulin deficiency combined with counterregulatory hormone excess

  27. DKA Diagnostic Criteria: • Glucose >250mg/dl • pH <7.3 • High anion gap • Positive ketones

  28. Clinical Features of DKA Precipitating events: • Inadequate insulin administration • Infection • Infarction • Drugs • Pregnancy

  29. Clinical Features of DKA Symptoms: • Nausea / vomiting • Thirst / polyuria • Abdominal pain • Shortness of breath

  30. Clinical Features of DKA Physical Findings: • Tachycardia • Dehydration / Hypotension • Tachypnea / Kussmaul respirations/ respiratory distress • Abdominal tenderness (may resemble acute pancreatitis or surgical abdomen) • Lethargy / obtundation / cerebral edema/ possibly coma

  31. Diagnosis DKA Anion Gap = Na – (Cl + HCO3) Normal: 8 - 12

  32. Management of DKA • Hydration • Insulin administration • Glucose monitoring • Electrolyte correction

  33. HHS • Prototype case is an elderly type 2 DM patient with several week history of polyuria, weight loss, ↓oral intake that culminates in mental confusion, lethargy or coma.

  34. Clinical features of HHS Precipitating events: • serious, concurrent illness (e.g. MI, CVA) • Sepsis, pneumonia, and other serious infections • debilitating condition (prior stroke or dementia) or social situation that compromises water intake

  35. Clinical features of HHS Physical findings: • Profound dehydration • Hypotension • Tachycardia • Altered mental status

  36. Clinical features of HHS Symptoms: • Notable absence of nausea, vomiting, and abdominal pain and the Kussmaul respirations

  37. HHS Diagnostic criteria: • Glucose >600mg/dl • Total serum osmolality >300mOsm/kg • Absence of severe ketoacidosis

  38. Management of HHS • Hydration • Insulin administration • Glucose monitoring • Electrolyte correction

  39. Chronic Complications of DM • Macrovascular (CAD, CVD, PVD) • Microvascular (retinopathy, nephropathy, neuropathy) • Others (e.g. GI, GU, dermatologic, infectious)

  40. Macrovascular Complications • Largest cause of morbidity and mortality • Risk of CVD increased 2 to 4 fold • Reduced survival post-MI. post-CABG, and particularly PTCA • Risk of stroke and PVD substantially increased

  41. Clinical Manifestations Heart • Angina pectoris • Acute MI • Silent MI • Arrhythmias

  42. Clinical Manifestations Brain • TIA (Transient ischemic attack) • RIND (Reversible Ischemic Neurological Deficits) • Stroke in evolution • Completed stroke (infarction,embolism, hge) • Lacunar infarcts

  43. Clinical Manifestations Limbs • Peripheral vascular disease (claudication; pain relieved by rest; pain does not go away with continued walk; primarily affects calves) • Poor wound healing, foot ulcers, gangrene

  44. Microvascular Complications DIABETES AGE’s Reactive oxygen species Diacyglycerol • protein cross-linking • accelerate atherosclerosis • promote glomerular dysfxn • ↓ NO synthesis • Induce endothelial dysfxn • Alter ECM composition & structure PKC activation MICROVASCULAR DAMAGE Retinopathy Neuropathy Nephropathy

  45. DM Retinopathy • DM is the leading cause of blindness in ages 20-74 in the US • Blindness is primarily the result of progressive diabetic retinopathy and clinically significant macular edema. • Incidence: • Found in almost all individuals with DM for > 20yrs and 25% incidence with 5 years, and 80% incidence with 15 years of type 1 DM

  46. Pathophysiology of DM Retinopathy loss of retinal pericytes ↑ retinal vascular permeability altered retinal blood flow abnormal retinal microvasculature Retinal Ischemia Neovascularization • Vitreous hemorrhage • Fibrosis Retinal Detachment

  47. Classifications of DM Retinopathy Stage I – Non-proliferative • Thickening of capillary endothelial BM • Reduction of pericytes • Microaneurysms • Multiple hemorrhages • Macular edema • Microvascular occlusion and ischemia

  48. Classifications of DM Retinopathy Stage II – Proliferative • Hallmark – Neovascularization in response to retinal hypoxia • newly formed vessels appear near the optic nerve and/or macula and rupture easily • vitreous hemorrhage, fibrosis • retinal detachment

More Related